We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Novasep to Sell its Bahamian Plant to Local Investor

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Novasep has announced that it has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem Technologies (Grand Bahama) Ltd (Pharmachem), to a local investor.

This facility produces a single product that is nearing the end of its life cycle and does not afford long-term viability for the site. Furthermore, the manufacturing capabilities of this facility did not support Novasep’s core strategy, which aims to position Novasep as a global supplier of contract manufacturing services for the life sciences’ molecules, based on a network of multipurpose synthesis facilities and differentiating technologies.

In this context, the group has sold the facility together with its business to a local investor who is focused on sustaining activity in the plant and maintaining local employment.

Commenting on this announcement, Michel Spagnol, chairman and CEO of Novasep said: “The divesture of Pharmachem is part of Novasep’s strategy to refocus on our core business and assets and to provide flexible and cost effective CMO services to the life sciences industry. I am glad to say that the divesture of this plant to a local investor is positive for both parties and Pharmachem’s employees.”